Join the Dementia group to help and get support from people like you.
Dementia News (Page 19)
Related terms: Chronic Brain Syndrome, DLB, Memory Loss
Higher Olive Oil Intake Tied to Lower Risk for Dementia-Related Death
WEDNESDAY, May 8, 2024 – Higher olive oil intake is associated with a lower risk for dementia-related mortality in U.S. adults, according to a study published online May 6 in JAMA Network Open. ...
Scientists May Have Located Your Brain's 'Neural Compass'
TUESDAY, May 7, 2024 – Researchers say they’ve identified a human “neural compass” – a pattern of brain activity that helps prevent humans from becoming lost. For the first time, the internal compa...
Gene Discovery Points to a New Form of Alzheimer's
TUESDAY, May 7, 2024 – People who carry two copies of the gene mutation most strongly implicated in Alzheimer’s disease are almost certain to develop brain changes related to the degenerative d...
Benefit of Thick Liquids in Alzheimer Disease and Dysphagia Unclear
MONDAY, May 6, 2024 – For hospitalized patients with Alzheimer disease and related dementias (ADRD) and dysphagia, those receiving thick liquids are less likely to be intubated but have no...
FDA Approves Adlarity (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease
BOSTON, March 14, 2022 /PRNewswire/ – Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies,...
FDA Approves Neuraceq (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Plaques
Berlin/Boston, March 20, 2014‒ Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq. This approval comes only four weeks after receiving marketing a...
Novartis Exelon Patch Now FDA Approved to Treat Patients Across all Stages of Alzheimer's Disease
EAST HANOVER, N.J., June 27, 2013 /PRNewswire/ – The US Food and Drug Administration (FDA) has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the...
Higher Dose of Novartis Drug Exelon Patch Approved By FDA for Patients With Mild to Moderate Alzheimer's Disease
EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ – The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with...
FDA Approves Amyvid (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
INDIANAPOLIS, April 6, 2012 /PRNewswire/ – Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA)...
FDA Medwatch Alert: Antipsychotics, Conventional and Atypical
[Posted 06/16/2008] FDA notified healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for...
FDA Medwatch Alert: Atypical Antipsychotic Drugs
The Food and Drug Administration has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved, “off-label” us...